Globin Solutions

Globin Solutions is a private, pre-clinical biotech developing novel antidotes for poisonings, with a lead program targeting carbon monoxide (CO). Its technology platform leverages engineered globin proteins, such as mutant neuroglobin and modified hemoglobins, which act as ultra-high-affinity scavengers to rapidly remove CO from the bloodstream. Founded in 2016 and supported by NIH STTR grants, the company aims to advance its lead candidates through preclinical development toward clinical testing, addressing a significant unmet medical need with no current antidotal therapy available.

Engineered human globin proteins (neuroglobin and hemoglobin mutants) designed as ultra-high-affinity scavengers to trap and remove toxic gases like carbon monoxide from the bloodstream.

There is no direct competitor with an approved pharmacological antidote for CO poisoning. The standard of care (100% oxygen, hyperbaric oxygen) represents the incumbent, albeit suboptimal, treatment. Any competitive threat would likely come from other early-stage biotechs exploring alternative scavenger molecules or therapeutic approaches.